Phase 2 expansions of OR502, an antibody targeting leukocyte immunoglobulin-like receptor B2 (LILRB2) ± cemiplimab in patients with advanced solid tumors.

Authors: Mohamad Adham Salkeni, David Sommerhalder, Andrae Lavon Vandross, Kamal D. Puri, Myriam N. Bouchlaka, Nenad Sarapa, Lesley Skingley, Mike Yefimenko, Alice Susannah Bexon, Damien Cronier, Shiraj Sen

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2669

Source: Full article

---

Abstract

TPS2669